ANNOVIS BIO ANNOUNCES PRICING OF $7.5 MILLION PUBLIC OFFERING

[nednedned]

irpages2.eqs.com/websites/a...

Annovis intends to use the net proceeds from this offering, together with its existing cash, for expenses primarily related to general corporate purposes, including to fund the clinical development of Annovis’ lead drug candidate, buntanetap, including the conduct of Annovis’ on-going and planned clinical trials, potential future commercialization efforts, and future regulatory activities including preparation of regulatory filings; and for additional early-stage research and development activities; and other general corporate purposes.

[Jmellano]

What does this mean for people with PD?

[ChucklesUSA in reply to Jmellano]

It means they have funding to complete the PD Phase 3 trial for buntanetap as well as a phase 2/3 in AD. PD data expected in January for more than 450 patients dosed for six months. Prior phase 2a was promising.

[Jmellano in reply to ChucklesUSA]

I hope it is good news for those who have PD, thst help may be on the way

[Pegcity]

I don't know if this is anything to write home about, but for those following the erratic journey of this company, here is a brief article about how plasma biomarkers have supported its claims.

businesswire.com/news/home/...